Share this article
Share this article
CAMBRIDGE, Mass., May 20, 2021 /PRNewswire/ Omega Therapeutics, Inc. ( Omega ), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics and pioneer novel DNA-sequence-based targets and develop a new class of mRNA-encoded programmable epigenetic medicines, today announced the appointment of Elliott M. Levy, M.D., to its Board of Directors. Dr. Levy is an industry veteran with over 20 years of research and development experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb. Elliott s extensive leadership experience in spearheading research and development strategy and operations at all stages of clinical development is a valuable addition to our team as we focus our efforts on further expanding the potential of our OMEGA platform across a broad array of diseases. Through his professional career at major pharmaceutical companies, Ellio
Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform
Funded by Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi and Takeda
The companies will support the rollout of a cloud-based platform with the potential to transform the way the biopharma industry communicates and exchanges information with health authorities worldwide.
BURLINGAME, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) Ten of the world s leading biopharmaceutical companies today announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission.
Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform
Funded by Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi and Takeda
The companies will support the rollout of a cloud-based platform with the potential to transform the way the biopharma industry communicates and exchanges information with health authorities worldwide.
BURLINGAME, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) Ten of the world’s leading biopharmaceutical companies today announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission.